Novavax | NVAX - Interest Expense On Debt


Novavax reported $5.82M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 2.1M 474K Mar/2026
Agenus USD 14.67M 1.35M Mar/2026
AstraZeneca USD 340M 144M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Cassava Sciences USD 108.37M 396.06M Mar/2026
Geron USD 7.15M 150K Mar/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
MannKind USD 14.82M 2.38M Jun/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 10.96B 527M Jun/2026
Novartis USD 281M 8M Sep/2025
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 667M 4M Jun/2026
Sanofi EUR 287M 109M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026